Telbivudine  	Telbivudine  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
chronic  	chronic  	 JJ	B-NP
hepatitis  	hepatitis  	 NNP	I-NP
B  	B  	 NNP	I-NP
infection  	infection  	 VBD	I-NP
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
telbivudine  	telbivudine  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
chronic  	chronic  	 JJ	B-NP
hepatitis  	hepatitis  	 NNP	I-NP
B  	B  	 NNP	I-NP
( 	( 	 -LRB-	O
CHB 	CHB 	 NNP	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
adults  	adults  	 NNS	O
based  	based  	 VBN	O
upon  	upon  	 IN	O
a  	a  	 DT	O
review  	review  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
National  	National  	 NNP	O
Institute  	Institute  	 NNP	O
for  	for  	 IN	O
Health  	Health  	 NNP	O
and  	and  	 CC	O
Clinical  	Clinical  	 NNP	B-NP
Excellence  	Excellence  	 NNP	I-NP
( 	( 	 -LRB-	O
NICE 	NICE 	 NNP	O
)  	)  	 -RRB-	O
as  	as  	 IN	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
single  	single  	 JJ	B-NP
technology  	technology  	 NN	I-NP
appraisal  	appraisal  	 NN	I-NP
( 	( 	 -LRB-	O
STA 	STA 	 NNP	B-NP
)  	)  	 -RRB-	O
process 	process 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
submission 	submission 	 NN	O
's  	's  	 POS	O
evidence  	evidence  	 NN	O
came  	came  	 VBD	O
from  	from  	 IN	O
one  	one  	 CD	O
randomised  	randomised  	 NNS	B-NP
controlled  	controlled  	 VBN	I-NP
trial  	trial  	 NN	I-NP
( 	( 	 -LRB-	O
RCT 	RCT 	 NNP	B-NP
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
GLOBE 	GLOBE 	 NNP	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
reasonable  	reasonable  	 JJ	O
methodological  	methodological  	 JJ	B-NP
quality  	quality  	 NN	I-NP
comparing  	comparing  	 VBG	I-NP
telbivudine  	telbivudine  	 NN	I-NP
with  	with  	 IN	O
lamivudine 	lamivudine 	 NN	B-NP
.  	.  	 .	O
One  	One  	 CD	O
other  	other  	 JJ	O
RCT  	RCT  	 NN	B-NP
that  	that  	 WDT	O
appeared  	appeared  	 VBD	O
to  	to  	 TO	O
meet  	meet  	 VB	O
the  	the  	 DT	O
inclusion  	inclusion  	 NN	B-NP
criteria  	criteria  	 NNS	I-NP
was  	was  	 VBD	O
excluded  	excluded  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
submission 	submission 	 NN	O
.  	.  	 .	O
For  	For  	 IN	O
the  	the  	 DT	O
primary  	primary  	 JJ	B-NP
outcome  	outcome  	 NN	I-NP
of  	of  	 IN	I-NP
therapeutic  	therapeutic  	 JJ	I-NP
response  	response  	 NN	I-NP
telbivudine  	telbivudine  	 NNS	I-NP
was  	was  	 VBD	O
statistically  	statistically  	 RB	O
superior  	superior  	 JJ	O
to  	to  	 TO	O
lamivudine  	lamivudine  	 VB	O
at  	at  	 IN	O
weeks  	weeks  	 NNS	O
52  	52  	 CD	O
and  	and  	 CC	O
104  	104  	 CD	O
for  	for  	 IN	O
hepatitis  	hepatitis  	 NNP	B-NP
B  	B  	 NNP	I-NP
e  	e  	 SYM	I-NP
antigen  	antigen  	 FW	I-NP
( 	( 	 -LRB-	O
HBeAg 	HBeAg 	 NNP	B-NP
) 	) 	 -RRB-	O
-positive  	-positive  	 JJ	O
patients 	patients 	 NNS	O
,  	,  	 ,	O
and  	and  	 CC	O
at  	at  	 IN	O
week  	week  	 NN	B-NP
104  	104  	 CD	O
for  	for  	 IN	O
HBeAg-negative  	HBeAg-negative  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
There  	There  	 EX	O
were  	were  	 VBD	O
statistically  	statistically  	 RB	O
significant  	significant  	 JJ	O
differences  	differences  	 NNS	O
in  	in  	 IN	O
favour  	favour  	 NN	O
of  	of  	 IN	O
telbivudine  	telbivudine  	 NN	B-NP
for  	for  	 IN	O
some  	some  	 DT	O
secondary  	secondary  	 JJ	B-NP
outcomes  	outcomes  	 NNS	I-NP
at  	at  	 IN	O
2  	2  	 CD	O
years  	years  	 NNS	O
including  	including  	 VBG	B-NP
hepatitis  	hepatitis  	 NNP	I-NP
B  	B  	 NNP	I-NP
virus  	virus  	 NN	I-NP
( 	( 	 -LRB-	O
HBV 	HBV 	 NNP	B-NP
)  	)  	 -RRB-	O
DNA  	DNA  	 NNP	B-NP
reduction 	reduction 	 NN	I-NP
,  	,  	 ,	O
HBV  	HBV  	 NNP	B-NP
DNA  	DNA  	 NNP	I-NP
non-detectability  	non-detectability  	 NNP	I-NP
and  	and  	 CC	O
alanine  	alanine  	 JJ	B-NP
aminotransferase  	aminotransferase  	 NNS	I-NP
normalisation  	normalisation  	 VBP	O
though  	though  	 RB	O
not  	not  	 RB	O
for  	for  	 IN	O
HBeAg-positive  	HBeAg-positive  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
HBeAg-positive  	HBeAg-positive  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
there  	there  	 EX	O
was  	was  	 VBD	O
no  	no  	 DT	O
significant  	significant  	 JJ	O
difference  	difference  	 NN	O
between  	between  	 IN	O
treatment  	treatment  	 NN	B-NP
groups  	groups  	 NNS	I-NP
for  	for  	 IN	I-NP
HBeAg  	HBeAg  	 JJ	I-NP
loss  	loss  	 NN	I-NP
or  	or  	 CC	O
seroconversion  	seroconversion  	 NN	B-NP
at  	at  	 IN	O
any  	any  	 DT	O
time  	time  	 NN	B-NP
point 	point 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
was  	was  	 VBD	O
similar  	similar  	 JJ	O
between  	between  	 IN	O
treatments 	treatments 	 NNS	O
.  	.  	 .	O
Two  	Two  	 CD	O
RCTs  	RCTs  	 JJ	B-NP
comparing  	comparing  	 JJ	I-NP
entecavir  	entecavir  	 NN	I-NP
with  	with  	 IN	O
lamivudine  	lamivudine  	 NN	B-NP
were  	were  	 VBD	O
included  	included  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
indirect  	indirect  	 JJ	O
comparison 	comparison 	 NN	O
;  	;  	 :	O
however 	however 	 RB	O
,  	,  	 ,	O
this  	this  	 DT	O
was  	was  	 VBD	O
poorly  	poorly  	 RB	O
conducted  	conducted  	 VBN	O
and  	and  	 CC	O
the  	the  	 DT	O
results  	results  	 NNS	O
should  	should  	 MD	O
be  	be  	 VB	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
caution 	caution 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
developed  	developed  	 VBD	O
two  	two  	 CD	O
economic  	economic  	 JJ	B-NP
models  	models  	 NNS	I-NP
to  	to  	 TO	O
determine  	determine  	 VB	O
the  	the  	 DT	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
telbivudine 	telbivudine 	 NN	I-NP
.  	.  	 .	O
Evidence  	Evidence  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
telbivudine  	telbivudine  	 NN	B-NP
and  	and  	 CC	O
lamivudine  	lamivudine  	 NNS	B-NP
was  	was  	 VBD	O
taken  	taken  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
GLOBE  	GLOBE  	 NNP	O
trial 	trial 	 NN	O
;  	;  	 :	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
adefovir  	adefovir  	 NN	B-NP
was  	was  	 VBD	O
based  	based  	 VBN	O
on  	on  	 IN	O
assumption 	assumption 	 NN	O
.  	.  	 .	O
There  	There  	 EX	O
was  	was  	 VBD	O
a  	a  	 DT	O
lack  	lack  	 NN	O
of  	of  	 IN	O
critical  	critical  	 JJ	B-NP
assessment  	assessment  	 NN	I-NP
and  	and  	 CC	O
assurance  	assurance  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
quality  	quality  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
data  	data  	 NNS	O
used  	used  	 VBN	O
to  	to  	 TO	O
populate  	populate  	 VB	O
the  	the  	 DT	O
models 	models 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
concluded  	concluded  	 VBD	O
that  	that  	 DT	O
telbivudine  	telbivudine  	 NN	B-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
cost-effective  	cost-effective  	 JJ	B-NP
option  	option  	 NN	I-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
lamivudine  	lamivudine  	 NNS	B-NP
using  	using  	 VBG	O
evidence  	evidence  	 NN	O
from  	from  	 IN	O
the  	the  	 DT	O
viral  	viral  	 JJ	B-NP
load  	load  	 NN	I-NP
model  	model  	 NN	I-NP
[ 	[ 	 -LRB-	O
HBeAg-positive  	HBeAg-positive  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
/ 	/ 	 VBP	I-NP
HBeAg-negative  	HBeAg-negative  	 JJ	I-NP
patients 	patients 	 NNS	I-NP
:  	:  	 :	O
mean  	mean  	 VB	O
incremental  	incremental  	 JJ	B-NP
cost  	cost  	 NN	I-NP
19,087  	19,087  	 CD	O
pounds 	pounds 	 CD	O
/ 	/ 	 CD	O
49,003  	49,003  	 CD	O
pounds 	pounds 	 NNS	O
,  	,  	 ,	O
mean  	mean  	 VBP	O
quality-adjusted  	quality-adjusted  	 JJ	B-NP
life-year  	life-year  	 NN	I-NP
( 	( 	 -LRB-	O
QALY 	QALY 	 NNP	B-NP
)  	)  	 -RRB-	O
gain  	gain  	 NN	O
1.30 	1.30 	 CD	O
/ 	/ 	 CD	O
4.67 	4.67 	 CD	O
,  	,  	 ,	O
incremental  	incremental  	 JJ	B-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
ratio  	ratio  	 NN	I-NP
( 	( 	 -LRB-	O
ICER 	ICER 	 NNP	B-NP
)  	)  	 -RRB-	O
14,665  	14,665  	 FW	O
pounds 	pounds 	 FW	O
/ 	/ 	 FW	O
10,497  	10,497  	 FW	O
pounds  	pounds  	 FW	O
per  	per  	 FW	O
QALY 	QALY 	 FW	B-NP
] 	] 	 -RRB-	O
.  	.  	 .	O
Resubmitted  	Resubmitted  	 JJ	B-NP
results  	results  	 NNS	I-NP
after  	after  	 IN	O
a  	a  	 DT	O
request  	request  	 NN	O
for  	for  	 IN	O
clarification  	clarification  	 NN	B-NP
by  	by  	 IN	O
the  	the  	 DT	O
ERG  	ERG  	 NNP	O
gave  	gave  	 VBD	O
less  	less  	 RBR	O
favourable  	favourable  	 JJ	O
ICERs  	ICERs  	 NN	B-NP
( 	( 	 -LRB-	O
HBeAg-positive  	HBeAg-positive  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
/ 	/ 	 VBP	I-NP
HBeAg-negative  	HBeAg-negative  	 JJ	I-NP
patients 	patients 	 NNS	I-NP
:  	:  	 :	O
mean  	mean  	 VB	O
incremental  	incremental  	 JJ	B-NP
cost  	cost  	 NN	I-NP
23,983  	23,983  	 CD	O
pounds 	pounds 	 CD	O
/ 	/ 	 CD	O
41,910  	41,910  	 CD	O
pounds 	pounds 	 NNS	O
,  	,  	 ,	O
mean  	mean  	 VBP	O
QALY  	QALY  	 JJ	B-NP
gain  	gain  	 NN	I-NP
1.56 	1.56 	 CD	O
/ 	/ 	 CD	O
2.07 	2.07 	 CD	O
,  	,  	 ,	O
ICER  	ICER  	 FW	B-NP
15,377  	15,377  	 FW	O
pounds 	pounds 	 FW	O
/ 	/ 	 FW	O
20,256  	20,256  	 FW	O
pounds  	pounds  	 FW	O
per  	per  	 FW	O
QALY 	QALY 	 FW	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
concluded  	concluded  	 VBD	O
that  	that  	 DT	O
telbivudine  	telbivudine  	 NN	B-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
cost-effective  	cost-effective  	 JJ	B-NP
option  	option  	 NN	I-NP
( 	( 	 -LRB-	O
on  	on  	 IN	O
its  	its  	 PRP$	O
own  	own  	 JJ	O
or  	or  	 CC	O
followed  	followed  	 VBN	O
by  	by  	 IN	O
adefovir 	adefovir 	 CD	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
have  	have  	 VBP	O
developed  	developed  	 VBN	B-NP
resistance  	resistance  	 NN	I-NP
to  	to  	 TO	O
first-line  	first-line  	 JJ	B-NP
telbivudine  	telbivudine  	 JJ	I-NP
treatment 	treatment 	 NN	I-NP
;  	;  	 :	O
however 	however 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
presentation  	presentation  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
results  	results  	 NNS	O
was  	was  	 VBD	O
not  	not  	 RB	O
ideal 	ideal 	 JJ	O
.  	.  	 .	O
In  	In  	 IN	O
conclusion 	conclusion 	 NN	O
,  	,  	 ,	O
although  	although  	 IN	O
telbivudine  	telbivudine  	 NN	B-NP
was  	was  	 VBD	O
statistically  	statistically  	 RB	O
superior  	superior  	 JJ	O
to  	to  	 TO	O
lamivudine  	lamivudine  	 VB	O
for  	for  	 IN	O
most  	most  	 RBS	O
antiviral  	antiviral  	 JJ	B-NP
outcomes 	outcomes 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
difference  	difference  	 NN	O
was  	was  	 VBD	O
not  	not  	 RB	O
clinically  	clinically  	 RB	O
significant 	significant 	 JJ	O
;  	;  	 :	O
in  	in  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
evidence  	evidence  	 NN	I-NP
for  	for  	 IN	O
telbivudine  	telbivudine  	 VBG	O
presented  	presented  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
was  	was  	 VBD	O
limited 	limited 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
NICE  	NICE  	 NNP	O
guidance  	guidance  	 VBD	O
issued  	issued  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
result  	result  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
STA  	STA  	 NNP	B-NP
states  	states  	 NNS	I-NP
that  	that  	 IN	O
telbivudine  	telbivudine  	 NN	B-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
recommended  	recommended  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
chronic  	chronic  	 JJ	B-NP
hepatitis  	hepatitis  	 NNP	I-NP
B  	B  	 NNP	I-NP
and  	and  	 CC	O
that  	that  	 IN	O
people  	people  	 NNS	O
currently  	currently  	 RB	O
receiving  	receiving  	 VBG	B-NP
telbivudine  	telbivudine  	 NNS	I-NP
should  	should  	 MD	O
have  	have  	 VB	O
the  	the  	 DT	O
option  	option  	 NN	O
to  	to  	 TO	O
continue  	continue  	 VB	O
therapy  	therapy  	 NN	O
until  	until  	 IN	O
they  	they  	 PRP	O
and  	and  	 CC	O
their  	their  	 PRP$	O
clinicians  	clinicians  	 NNS	B-NP
consider  	consider  	 VBP	O
it  	it  	 PRP	O
appropriate  	appropriate  	 JJ	O
to  	to  	 TO	O
stop 	stop 	 VB	O
.  	.  	 .	O
